Generic Latisse Availability
Last updated on Jun 8, 2022.
Latisse is a brand name of bimatoprost topical, approved by the FDA in the following formulation(s):
LATISSE (bimatoprost - solution/drops;topical)
Has a generic version of Latisse been approved?
A generic version of Latisse has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Latisse and have been approved by the FDA:
bimatoprost solution/drops;topical
-
Manufacturer: AKORN
Approval date: October 9, 2018
Strength(s): 0.03% [AT] -
Manufacturer: ALEMBIC PHARMS LTD
Approval date: January 21, 2020
Strength(s): 0.03% [AT] -
Manufacturer: APOTEX INC
Approval date: December 1, 2014
Strength(s): 0.03% [AT] -
Manufacturer: SANDOZ INC
Approval date: April 19, 2016
Strength(s): 0.03% [AT]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Latisse. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Method of enhancing hair growth
Patent 8,038,988
Issued: October 18, 2011
Inventor(s): Woodward; David F. & VanDenburgh; Amanda M.
Assignee(s): Allergan, Inc.Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.
Patent expiration dates:
- August 25, 2023✓✓✓
- August 25, 2023
-
Method of enhancing hair growth
Patent 8,101,161
Issued: January 24, 2012
Inventor(s): Woodward; David F. & VanDenburgh; Amanda M.
Assignee(s): Allergan, Inc.Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.
Patent expiration dates:
- May 25, 2024✓
- May 25, 2024✓
- May 25, 2024
-
Method of enhancing hair growth
Patent 8,263,054
Issued: September 11, 2012
Inventor(s): Woodward; David F. & Vandenburgh; Amanda M
Assignee(s): Allergan, Inc.Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.
Patent expiration dates:
- January 15, 2023✓
- January 15, 2023
-
Method of enhancing hair growth
Patent 8,632,760
Issued: January 21, 2014
Assignee(s): Allergan, Inc.Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.
Patent expiration dates:
- January 15, 2023✓
- January 15, 2023
-
Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
Patent 8,758,733
Issued: June 24, 2014
Assignee(s): Allergan, Inc.The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.
Patent expiration dates:
- January 15, 2023✓
- January 15, 2023
-
Method of enhancing hair growth
Patent 8,986,715
Issued: March 24, 2015
Assignee(s): Allergan, Inc.Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.
Patent expiration dates:
- January 15, 2023✓
- January 15, 2023
-
Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
Patent 9,216,183
Issued: December 22, 2015
Assignee(s): Allergan, Inc.The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.
Patent expiration dates:
- January 15, 2023✓
- January 15, 2023
-
Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
Patent 9,226,931
Issued: January 5, 2016
Assignee(s): Allergan, Inc.The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.
Patent expiration dates:
- January 15, 2023✓
- January 15, 2023
More about Latisse (bimatoprost topical)
- Side effects
- Drug interactions
- Dosage information
- During pregnancy or Breastfeeding
- Reviews (3)
- Pricing & coupons
- En español
- Drug class: miscellaneous topical agents
- FDA approval history
Patient resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
AT | Topical products. There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays and suppositories. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of in vivo bioequivalence has been granted and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded AT. Pharmaceutically equivalent topical products that raise questions of bioequivalence, including all post-1962 non-solution topical drug products, are coded AB when supported by adequate bioequivalence data, and BT in the absence of such data. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.